

MEDICREA: LISTING WILL RESUME ON JULY 17,2020

Lyon and New York, July 16, 2020 – The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED; OTCQX Best Market –MRNTF), is pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNID[™] ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies.

Due to the publication of a press release announcing MEDTRONIC's proposed friendly public offer for MEDICREA®, the Company wished to briefly suspend its listing to allow better dissemination of this information and the press release describing the transaction. Listing will resume on July 17, 2020.

About MEDICREA® (www.medicrea.com)

Through the lens of predictive medicine, MEDICREA® leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a \$10 billion marketplace, MEDICREA® is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 35 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

For further information, please visit: medicrea.com.

Connect with MEDICREA® FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

MEDICREA® Denys SOURNAC Founder, Chairman and CEO <u>dsournac@medicrea.com</u>

Fabrice KILFIGER Chief Financial Officer fkilfiger@medicrea.com

Tel: +33 (0)4 72 01 87 87

MEDICREA® is listed on EURONEXT Growth Paris EnterNext PEA PME 150 Index ISIN: FR 0004178572 Ticker: ALMED LEI: 969500BR1CPTYMTJBA37



MEDICREA® is traded on OTCQX Best Market Ticker: MRNTF

